AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

Betsy Goodfellow | September 22, 2023 | News story | Research and Development AstraZeneca, Daiichi Sankyo, Oncology, breast cancer, clinical trial 

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, which showed datopotamab deruxtecan (Dato-DXd) demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy in patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.

The trial not only showed the significant improvement in PFS, but also a trend in improvement for the dual primary endpoint of overall survival (OS) compared to chemotherapy. Data for OS was not mature at the stage of interim analysis meaning the trial will continue to assess this.

The drug’s safety profile remained consistent with previous clinical trials for this indication, and no new safety signals were identified.

Susan Galbraith, executive vice president of oncology R&D at AstraZeneca, commented: “Today’s TROPION-Breast01 news is a significant development for patients with HR-positive, HER2-low or negative metastatic breast cancer whose tumours have become insensitive to endocrine therapy and who currently face poor outcomes. We are encouraged by these positive results.”

This data is expected to be published at an upcoming medical meeting and will be shared with the relevant health authorities.

Betsy Goodfellow

Related Content

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

Tolremo Therapeutics has announced that it has dosed the first patient in its first-in-human clinical …

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …

testalize-me-0je8ynv4mis-unsplash

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

GSK has announced positive results from a planned interim efficacy analysis of the phase 3 …

Latest content